MedTrace Logo

Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma

NCT07346404 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-16

No results posted yet for this study

Summary

This is a pilot prospective longitudinal monocentric, non-comparative, nonrandomised, and non-controlled open study.

is to test whether the intensity of 82-Rb uptake on PET acquisitions is associated to the aggressiveness of RCC on histology (ISUP grades), i.e., to successfully identify high-grade (ISUP grades 3 and 4) vs. lowgrade (ISUP grades 1 and 2) RCC.

Conditions

Interventions

DRUG

82-Rb injection

Injection of 82-Rb for 82-Rb PET imaging

Sponsors & Collaborators

  • Naogen Pharma

    collaborator UNKNOWN

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Marc-Olivier TIMSIT · Assistance Publique - Hôpitaux de Paris

  • Fabrien HYAFIL · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2028-01-01
Completion
2028-01-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07346404 on ClinicalTrials.gov